Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) rose 1.1% during mid-day trading on Thursday . The company traded as high as GBX 589.94 and last traded at GBX 530. Approximately 7,194 shares changed hands during trading, a decline of 68% from the average daily volume of 22,654 shares. The stock had previously closed at GBX 524.
Hemogenyx Pharmaceuticals Trading Up 1.1%
The stock has a 50 day moving average of GBX 679.63 and a 200 day moving average of GBX 802.14. The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72. The firm has a market cap of £36.04 million, a P/E ratio of -3.11 and a beta of 1.50.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
See Also
- Five stocks we like better than Hemogenyx Pharmaceuticals
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
